In clinical trial follow-ups, most participants began regaining weight within the first 3 months after stopping GLP-1 therapy
It is against that surge in demand that a parallel, unregulated category has grown around the drugs name
Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases
Merck plans to leverage its expertise in incretin biology to fully evaluate the potential of HS-10535, especially its possible additional cardiovascular and metabolic benefits beyond weight loss
Note that if you take levothyroxine, co-administration with Rybelsus may increase thyroid hormone exposure
Your metabolic rate and satiety signals typically stay enhanced during this window, allowing you to maintain eating patterns without significant hunger increase